Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.

After being burned by Point, Lilly is taking a slower approach with Radionetics.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.

The EU recommendation for odronextamab comes after a US rejection in March.

But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.

Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.

Earnings season begins again, while big readouts loom for ALX and Fibrogen.